Navigation Links
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Date:2/17/2011

TARRYTOWN, N.Y., Feb. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones.  

"2010 was a very productive year for Regeneron as we reported positive Phase 3 results in four clinical trials: two with VEGF Trap-Eye in wet age-related macular degeneration, called wet AMD, one with VEGF Trap-Eye in central retinal vein occlusion, and one with ARCALYST® for the prevention of gout flares in patients initiating uric-acid lowering therapy," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "We expect regulatory applications to be filed in the first half of 2011 for marketing approval in the U.S. and Europe for VEGF Trap-Eye in wet AMD.  We also look forward to reporting results from additional Phase 3 trials in central retinal vein occlusion and gout and from two Phase 3 trials with aflibercept in cancer."

"In anticipation of potential product approvals," Dr. Schleifer added, "we are continuing to build our commercialization capabilities.  We are also advancing our earlier-stage pipeline which currently includes eight fully-human monoclonal antibodies in clinical development for the treatment of various diseases and conditions including elevated LDL cholesterol, rheumatoid arthritis, atopic dermatitis, and cancer.  We anticipate Phase 2 data from some of these programs in 2011."

"We entered 2011 in a strong financial position to support our development and commercialization activities," commented Murray A. Goldberg, Chief Financial Officer, "with approximately $627 million in cash and securities, following a successful public offering of Common Stock in October 2010."

Clinical Programs UpdateVEGF Trap-Eye (aflibercept opht
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global ... Depository Trust Company (DTC) has made their final ... Chill on the Company,s stock effective December 15, ... common stock for depository and book entry transfer ... Company is now once again fully "DTC Eligible", ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Inc. (NYSE: LDR ), a recognized leader ... and high quality medical consumable accessories, today reported financial results ... Fiscal 2012 Second Quarter Highlights ... prior year period. , Gross profit grew 11 percent ...
... Inc. (NASDAQ: UPI ), a medical device ... for the treatment of voiding dysfunctions, announced today that ... President and CFO, will present the Company,s business strategy ... JMP Securities Research Conference at 12:30 pm PT on Monday, ...
Cached Medicine Technology:Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 12Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 13Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 14Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 15Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 16Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 17Uroplasty to Present at the 11th Annual JMP Securities Research Conference 2
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at ... of its kind, the site has provided its faithful users ... years running. It uniquely combines the benefits of platforms ... available to the masses. Assuring the potent herb’s followers ... of public approval. , Shane Chattin, Owner of ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has ... business has drastically cut prices to all its prom ... Jan. 30, 2015. Many of the hottest styles are ... lace dresses, and more. , A spokesman for MissyDress ... Whether A-line princess prom dresses or sweetheart chiffon prom ...
(Date:12/20/2014)... The print component of Healthy Aging ... of approximately 160,000 copies and an estimated readership of ... vast social media strategy and across a network of ... digital version of the campaign, click here . ... the ladies of CTV’s The Social. Lainey Lui, ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... 2014 Xarelto bleeding lawsuits filed ... uncontrollable bleeding and other serious side effects will be ... Louisiana for coordinated pretrial proceedings, Wright & Schulte LLC ... issued an order Friday to transfer 21 Xarelto lawsuits ... federal courts to the Louisiana district court for coordination ...
Breaking Medicine News(10 mins):Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4
... E. Lachman has been awarded a $1.45 million five-year ... more about factors that can minimize memory declines in ... beliefs and behaviors that are tied to better memory ... and older adults believe that memory declines are inevitable ...
... Jobson Medical Information LLC,("JMI"), a leading ... it has acquired Gerber Communications ("Gerber") and,Practice ... leading,providers of custom publishing services and training ... acquisition expands JMI,s ability to,reach eye care ...
... Medical Center today,announced the use of an investigational, ... treatment of heart rhythm,disorders that can result in ... first performed in Texas as part of the ... taking place at up,to 25 hospitals throughout the ...
... other systemic uses of drugs to ... growth factor (VEGF), BOSTON, Feb. 13 New research ... the anti-cancer drug Avastin,which targets a growth factor responsible for ... certain patients.,Institute scientists mimicked the drug,s activity in mice and ...
... speech,pathologist and autism consultant Valerie Herskowitz will present ... the "Autism Through,the Lifespan" conference to be held ... now for an entire generation of children challenged ... and becoming young,adults with autism. Technology is the ...
... MALVERN, Pa., Feb. 13 A new study ... medical expenses reported,by auto injury claimants continue to ... economic losses (which include expenses for,medical care, lost ... claimants grew 9 percent annualized, from $5,520 in ...
Cached Medicine News:Health News:Brandeis researcher awarded grant to investigate memory and aging 2Health News:Jobson Medical Information LLC Acquires Gerber Communications and Practice Advancement Associates 2Health News:St. David's Medical Center First in Texas to Implement Visually Guided Catheter Ablation for Atrial Fibrillation 2Health News:VEGF Neutralization Can Damage Brain Vessels, Say Schepens Eye Research Institute Scientists 2Health News:A Sneak Peek Into the Special Needs Home of Tomorrow - Renowned Autism Consultant Valerie Herskowitz to Present Latest Findings at 'Autism Through the Lifespan' Conference February 14-17 in Orlando 2Health News:IRC Reports Claimed Medical Expenses for Auto Injury Claimants Far Outpace Inflation 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: